Literature DB >> 12564638

Cyclic nucleotide phosphodiesterase isozymes expressed in mouse skeletal muscle.

Timothy J Bloom1.   

Abstract

To understand changes in cyclic nucleotide metabolism in muscle disease states, the expression of phosphodiesterase (PDE) isozymes in normal mouse leg muscle was examined. Four subcellular fractions were generated by differential centrifugation at 10,000 x g and 100,000 x g. cAMP PDE activity was found predominately in the soluble fractions, while cGMP PDE activity was more evenly distributed amongst soluble and particulate fractions. Pharmacological inhibitors demonstrate that PDE4 represents the major cAMP hydrolyzing activity and PDE2 represents the major cGMP hydrolyzing activity in mouse leg muscle. PDE1 is expressed at low levels, while PDE3 and PDE5 are intermediate. Between 20 and 40% of total PDE activity remained in the presence of inhibitors for PDE1-PDE5, indicating that other PDE families contribute to the total PDE pool. Reverse-transcription PCR with family-specific primers showed expression of mRNA for PDE7-PDE9, supporting this conclusion. Total PDE activity was found to be elevated in tissue extracts from a mouse model of Duchenne's muscular dystrophy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12564638     DOI: 10.1139/y02-149

Source DB:  PubMed          Journal:  Can J Physiol Pharmacol        ISSN: 0008-4212            Impact factor:   2.273


  15 in total

Review 1.  Nitric Oxide Regulates Skeletal Muscle Fatigue, Fiber Type, Microtubule Organization, and Mitochondrial ATP Synthesis Efficiency Through cGMP-Dependent Mechanisms.

Authors:  Younghye Moon; Jordan E Balke; Derik Madorma; Michael P Siegel; Gary Knowels; Peter Brouckaert; Emmanuel S Buys; David J Marcinek; Justin M Percival
Journal:  Antioxid Redox Signal       Date:  2016-08-17       Impact factor: 8.401

2.  Genetic inhibition of PKA phosphorylation of RyR2 prevents dystrophic cardiomyopathy.

Authors:  Satyam Sarma; Na Li; Ralph J van Oort; Corey Reynolds; Darlene G Skapura; Xander H T Wehrens
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-06       Impact factor: 11.205

Review 3.  Effects of cyclic nucleotide phosphodiesterases (PDEs) on mitochondrial skeletal muscle functions.

Authors:  Liliane Tetsi; Anne-Laure Charles; Stéphanie Paradis; Anne Lejay; Samy Talha; Bernard Geny; Claire Lugnier
Journal:  Cell Mol Life Sci       Date:  2016-12-30       Impact factor: 9.261

4.  Evaluation of the therapeutic utility of phosphodiesterase 5A inhibition in the mdx mouse model of duchenne muscular dystrophy.

Authors:  Justin M Percival; Candace M Adamo; Joseph A Beavo; Stanley C Froehner
Journal:  Handb Exp Pharmacol       Date:  2011

Review 5.  cAMP signaling in skeletal muscle adaptation: hypertrophy, metabolism, and regeneration.

Authors:  Rebecca Berdeaux; Randi Stewart
Journal:  Am J Physiol Endocrinol Metab       Date:  2012-02-21       Impact factor: 4.310

Review 6.  Alterations of cAMP-dependent signaling in dystrophic skeletal muscle.

Authors:  Rüdiger Rudolf; Muzamil M Khan; Danilo Lustrino; Siegfried Labeit; Isis C Kettelhut; Luiz C C Navegantes
Journal:  Front Physiol       Date:  2013-10-17       Impact factor: 4.566

7.  Vascular-targeted therapies for Duchenne muscular dystrophy.

Authors:  James P Ennen; Mayank Verma; Atsushi Asakura
Journal:  Skelet Muscle       Date:  2013-04-23       Impact factor: 4.912

8.  Sarcolemma-localized nNOS is required to maintain activity after mild exercise.

Authors:  Yvonne M Kobayashi; Erik P Rader; Robert W Crawford; Nikhil K Iyengar; Daniel R Thedens; John A Faulkner; Swapnesh V Parikh; Robert M Weiss; Jeffrey S Chamberlain; Steven A Moore; Kevin P Campbell
Journal:  Nature       Date:  2008-10-26       Impact factor: 49.962

9.  Primary role of functional ischemia, quantitative evidence for the two-hit mechanism, and phosphodiesterase-5 inhibitor therapy in mouse muscular dystrophy.

Authors:  Akihiro Asai; Nita Sahani; Masao Kaneki; Yasuyoshi Ouchi; J A Jeevendra Martyn; Shingo Egusa Yasuhara
Journal:  PLoS One       Date:  2007-08-29       Impact factor: 3.240

10.  Role of phosphodiesterase 4 expression in the Epac1 signaling-dependent skeletal muscle hypertrophic action of clenbuterol.

Authors:  Yoshiki Ohnuki; Daisuke Umeki; Yasumasa Mototani; Kouichi Shiozawa; Megumi Nariyama; Aiko Ito; Naoya Kawamura; Yuka Yagisawa; Huiling Jin; Wenqian Cai; Kenji Suita; Yasutake Saeki; Takayuki Fujita; Yoshihiro Ishikawa; Satoshi Okumura
Journal:  Physiol Rep       Date:  2016-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.